BioHarvest Sciences Inc. Common Stock (BHST)
Fast GrowerFairStock Score: 51/100 — MIXED
Key Financials
| Current Price | $4.1 |
| Market Cap | $100M |
| P/E Ratio | -7.07 |
| ROE | -83.17% |
| Dividend Yield | —% |
| Sector | Consumer Defensive |
Strengths
- Revenue growth of 24.6% demonstrates strong top-line momentum
Concerns
- Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
- Weak Piotroski F-Score of 3/9 suggests deteriorating financial quality across multiple dimensions
- Altman Z-Score of 0.2 places it in the financial distress zone—elevated bankruptcy risk
AI Analysis
BioHarvest Sciences Inc. Common Stock is a micro-cap consumer defensive company valued at $100 million. Revenue stands at $35 million, though the company is currently unprofitable. From a quality standpoint, BioHarvest shows weak Piotroski F-Score of 3/9 signaling deteriorating fundamentals and distressed Altman Z-Score of 0.2 warrants caution. Growth dynamics show revenue growing at 24.6% and profit growth of 25.4%. Our composite FairStock Score of 51/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.
Bull Case
BioHarvest's 25% revenue growth trajectory could accelerate as it captures additional market share in the consumer defensive sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.
Bear Case
Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer